\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesThe Digital Europe programme provides funds for the acquisition of JUPITER, the first exascale computer in Europe.
JUPITER will contain high-powered, energy efficient processors, including also first prototypes of ‘made in the EU’ processors. Its computing power will support the development of high-precision models of complex systems and applications, such as:
After its installation in the second half of 2024, JUPITER will be made available to the scientific community, industries, and the public sector across Europe. Hundreds of applications will be run in areas such as climate change and weather forecasting, material science, bio-engineering, and training large language models. Jupiter will be accessible to startups across Europe to train and deploy generative AI models.
Once operational JUPITER joins the existing supercomputers of the EuroHPC JU already in operation: MareNostrum in Spain, LEONARDO in Italy, LUMI in Finland, Discoverer in Bulgaria, MeluXina in Luxembourg, Vega in Slovenia, Karolina in Czechia, and Deucalion in Portugal – all combining to put a total of almost two billion billion calculations per second, thus confirming Europe as a world supercomputing power.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Civil Security Digital, Industry & Space Agro-Food, Environment
The European Innovation Council has launched a call to recruit independent experts of diverse innovative defence and dual-use technologies (as eg. maritime, medical, drones, financial expertise, ..). It is important for the EIC to have a solid batch of experts with a balanced national diversity. Note that, as a requirement and due to security sens... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
